Scholarlink

Purpose <p>This study aimed to isolate and characterize bioactive compounds from the roots of <i>Garcinia atroviridis</i> and evaluate their potential anticancer activity, particularly against breast cancer (BC), through network pharmacology and in-silico approaches.</p> Methods <p>Compounds were isolated from the ethyl acetate (EtOAc) extract of <i>G. atroviridis</i> roots using chromatographic and spectroscopic techniques. Their anticancer potential was assessed through network pharmacology analyses, including target prediction, protein–protein interaction (PPI) network construction, and enrichment analyses using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. Molecular docking and 150-nanosecond molecular dynamics (MD) simulations were conducted to evaluate the binding affinity and stability of compound-target interactions.</p> Results <p>Five phenolic compounds, namely atrovirisidone, 1,3,5-trihydroxy-2-methoxyxanthone, GB1a, volkensiflavone, and morelloflavone, were successfully identified. Network analyses highlighted HIF1A, ITGB1, RET, HDAC2, and MAPK1 as key molecular targets. GO and KEGG analyses revealed that these targets are associated with cancer-related pathways. All compounds demonstrated strong binding affinities to HIF1A, with docking energies ranging from − 33.02 to − 51.19&#xa0;kcal/mol, outperforming standard ligands. Among them, morelloflavone exhibited the strongest interaction and stable binding, as confirmed by MD simulations.</p> Conclusion <p>The phenolic compounds from <i>G. atroviridis</i>, particularly morelloflavone, exhibit significant potential as anticancer agents by modulating HIF1A-related pathways. These findings support further investigation of morelloflavone as a lead compound for breast cancer therapeutics.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Unveiling the Potential of Garcinia Atroviridis Root-Derived Phenolic Compounds Against Breast Cancer: Isolation, Network Pharmacology and In-Silico Approaches

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月4日

查看全文
  • Nur Salsabila Binti Ahmad Roslan,
  • Miah Roney,
  • Abdul Rashid Issahaku,
  • Md. Nazim Uddin,
  • Mohd Fadhlizil Fasihi Mohd Aluwi,
  • Seema Zareen,
  • Anke Wilhelm,
  • Ahmad Mahfuz Gazali,
  • Muhammad Nadeem Akhtar,
  • Normaiza Binti Zamri

摘要

Purpose

This study aimed to isolate and characterize bioactive compounds from the roots of Garcinia atroviridis and evaluate their potential anticancer activity, particularly against breast cancer (BC), through network pharmacology and in-silico approaches.

Methods

Compounds were isolated from the ethyl acetate (EtOAc) extract of G. atroviridis roots using chromatographic and spectroscopic techniques. Their anticancer potential was assessed through network pharmacology analyses, including target prediction, protein–protein interaction (PPI) network construction, and enrichment analyses using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. Molecular docking and 150-nanosecond molecular dynamics (MD) simulations were conducted to evaluate the binding affinity and stability of compound-target interactions.

Results

Five phenolic compounds, namely atrovirisidone, 1,3,5-trihydroxy-2-methoxyxanthone, GB1a, volkensiflavone, and morelloflavone, were successfully identified. Network analyses highlighted HIF1A, ITGB1, RET, HDAC2, and MAPK1 as key molecular targets. GO and KEGG analyses revealed that these targets are associated with cancer-related pathways. All compounds demonstrated strong binding affinities to HIF1A, with docking energies ranging from − 33.02 to − 51.19 kcal/mol, outperforming standard ligands. Among them, morelloflavone exhibited the strongest interaction and stable binding, as confirmed by MD simulations.

Conclusion

The phenolic compounds from G. atroviridis, particularly morelloflavone, exhibit significant potential as anticancer agents by modulating HIF1A-related pathways. These findings support further investigation of morelloflavone as a lead compound for breast cancer therapeutics.